Curevo
Curevo develops vaccines for varicella and herpes zoster, with a lead product candidate, amezosvatein, an adjuvanted subunit vaccine for the prevention of shingles in adults. The organization aims to improve patient experience and vaccination rates by offering a vaccine with non-inferior efficacy and improved reactogenicity compared to existing options.
Facts
- HQ
- Bothell, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2017
- Employees
- 30
- Stage
- Series B
- Members see funding amounts. .
Is this your organization? Claim it
Curevo Raises $110M Series B to Advance Shingles Vaccine Amid GSK Competition, Adds Former GSK and Moderna Execs to Board
Seattle biotech startup Curevo raised $110 million in a Series B round to advance Phase 2 trials of its shingles vaccine amezosvatein, competing with GlaxoSmithKline's Shingrix. The company added biotech veterans, including former GSK and Moderna executives, to its board to support development.
Curevo raises $60M to test shingles vaccine vs. GSK’s $2.3B-a-year Shingrix in 650+ person phase 2b trial
Seattle vaccine startup Curevo raised $60 million to fund a phase 2b trial comparing its shingles vaccine against GSK’s market-leading Shingrix, aiming to reduce side effects while preserving strong immune responses. The shot uses a non-living viral component plus a proprietary adjuvant and was developed through a 2018 partnership including GC Pharma, the Mogam Institute, and Seattle’s IDRI.
Online
Questions about Curevo
What is Curevo?
Curevo is a startup developing vaccines for varicella and herpes zoster, based in Bothell, Washington, US.
What is Curevo known for?
Curevo is known for its lead product candidate, amezosvatein, an adjuvanted subunit vaccine intended to prevent shingles in adults. Curevo aims to offer non-inferior efficacy and improved reactogenicity compared to existing options.
What has Curevo been in the news for?
GeekWire reported in March 2025 on Curevo advancing its shingles vaccine amid competition from GSK. In February 2022, GeekWire reported on plans to test Curevo’s shingles vaccine against GSK’s Shingrix.
Who invested in Curevo, and how much has it raised?
Members of Seattle Flow see Curevo's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Curevo based?
Curevo is based in Bothell, Washington, US.
When was Curevo founded?
Curevo was founded in 2017.